iMDx Q2 Loss Deepens, Cash Runway Tightens; FDA Dialogue Continues
IMDX has more than doubled off its 52-week low of $2.33 on light trading volume (0.3× avg).
Summary
iMDx's Q2 loss widened to $11.3M on only $239K in revenue. Cash is $17.8M and the company flagged going concern risks, though management expects to have sufficient liquidity for the next year. FDA review of its lead transplant test continues.
Key Events · Earnings and Guidance · IMDX
-
Q2 Loss Widens
The net loss deepened to $11.3M from $9.7M a year ago, on revenue of just $239K. Operating cash burn hit $16.9M in H1 2026.
-
Cash Runway Under Pressure
Cash and equivalents fell to $17.8M from $25.8M at year-end 2025. Despite raising $24.6M net in February 2026, the company is burning cash rapidly.
-
Going Concern Risk Flagged
Management's evaluation raised substantial doubt about the company's ability to continue as a going concern, though it believes cost-cutting and potential future financings will provide sufficient liquidity for at least 12 months.
-
FDA Review Ongoing
The FDA is still reviewing the GraftAssureDx submission made in March 2026. No approval timeline was provided, but the company described dialogue as 'meaningful and productive.'
Analysis · IMDX · Life Sciences
Insight Molecular Diagnostics posted a wider Q2 net loss of $11.3 million on just $239,000 in revenue, with operating cash burn reaching $16.9 million in the first half. Cash stands at $17.8 million, and the company's own going concern evaluation acknowledges substantial doubt about its ability to continue, though management believes its cost-cutting and financing plans will bridge the next twelve months. The FDA is still reviewing the GraftAssureDx submission, with no approval timeline given. A recent Medicare LCD expansion is a tailwind, but the immediate focus is on whether the company can fund operations long enough to reach commercialization.
At the time of this filing, IMDX was trading at $4.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $154M. The 52-week trading range was $2.33 to $8.51. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.